Canaccord Genuity Maintains Hold on Staar Surgical, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Jon Young maintains a Hold rating on Staar Surgical (STAA) and raises the price target from $32 to $46.
April 08, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Hold rating on Staar Surgical but raises the price target from $32 to $46.
The increase in price target from $32 to $46 by Canaccord Genuity suggests a positive outlook on Staar Surgical's future performance, potentially leading to increased investor interest and a short-term positive impact on the stock price. However, the Hold rating indicates that the analyst believes the stock might not significantly outperform the market in the near term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100